COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,633 Articles (22,913 medRxiv, 8,720 bioRxiv)

Most recent first Previous |  Page 387: Articles 3861-3870  | Next

The molecular reach of antibodies determines their SARS-CoV-2 neutralisation potency
Huhn, A., Nissley, D. A., Wilson, D. B., Kutuzov, M. A., Donat, R., Tan, T. K., Zhang, Y., Barton, M. I., Liu, C., Dejnirattisai, W., Supasa, P., Mongkolsapaya, J., Townsend, A., James, W. S., Screaton, G., van der Merwe, P. A., Deane, C., Isaacson, S., Dushek, O.
10.1101/2023.09.06.556503 — Posted: 2023-09-07
Convergent Sequence Features of Antiviral B Cells
Abu-Shmais, A. A., Vukovich, M. J., Wasdin, P. T., Suresh, Y. P., Rush, S. A., Gillespie, R. A., Sankhala, R. S., Choe, M., Joyce, M. G., Kanekiyo, M., McLellan, J. S., Georgiev, I. S.
10.1101/2023.09.06.556442 — Posted: 2023-09-07
Immunogenicity and tolerability of a SARS-CoV-2 TNX-1800, a live recombinant poxvirus vaccine candidate, in Syrian Hamsters and New Zealand White Rabbits.
Awasthi, M., Macaluso, A., Goebel, S. J., Luea, E., Noyce, R. S., Nasar, F., Daugherty, B., Bavari, S., Lederman, S.
10.1101/2023.09.06.556620 — Posted: 2023-09-07
Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
Aboshi, M., Matsuda, K., Kawakami, D., Kono, K., Kazami, Y., Sekida, T., Komori, M., Morey, A. L., Suga, S., Smith, J. F., Fukuhara, T., Iwatani, Y., Yamamoto, T., Sato, N., Akahata, W.
10.1101/2023.09.04.23294493 — Posted: 2023-09-06
Serological outcomes of SARS-CoV-2 infection by vaccination status and variant in England
Quinot, C., Lunt, R., Kirsebom, F., Andrews, N., Whitaker, H., Skarnes, C., Letley, L., Haskins, D., Angel, C., Firminger, S., Ratcliffe, K., Sheridan, A., Rajan, S., Akindele, L., Ijaz, S., Zambon, M., Brown, K., Ramsay, M., Lopez Bernal, J.
10.1101/2023.09.05.23295073 — Posted: 2023-09-06
IMPACT OF THE COVID-19 PANDEMIC ON ROUTINE HIV CARE AND ANTIRETROVIRAL TREATMENT OUTCOMES IN KENYA: A NATIONALLY REPRESENTATIVE ANALYSIS
Kimanga, D. O., Makory, V. N. B., Hassan, A. S., Ngari, F., Ndisha, M. M., Muthoka, K. J., Odero, L., Omoro, G. O., Aoko, A., Ng'ang'a, L.
10.1101/2023.09.04.23294973 — Posted: 2023-09-06
SARS-CoV-2 quarantine mandated by contact tracing: burden and infection rate among close contacts in Zurich, Switzerland, 2020-2021
Aschmann, H. E., Domenghino, A., Jung, R., Ballouz, T., Menges, D., Fehr, J., Puhan, M. A.
10.1101/2023.09.03.23294798 — Posted: 2023-09-05
A Literature Review and Meta-Analysis of the Effects of Lockdowns on COVID-19 Mortality - II
Herby, J., Jonung, L., Hanke, S.
10.1101/2023.08.30.23294845 — Posted: 2023-09-05
Bivalent mRNA vaccine effectiveness against COVID-19 infections, hospitalisations and deaths in Portugal: a cohort study based on electronic health records, September 2022 to May 2023
Machado, A., Kislaya, I., Soares, P., Magalhaes, S., Rodrigues, A. P., Franco, R., Leite, P. P., Dias, C. M., Nunes, B.
10.1101/2023.09.05.23295025 — Posted: 2023-09-05
Individual and spatial determinants of mortality during the Covid-19 pandemic: The case of Belgium in 2020
Bourguignon, M., Bertrand, A., Damiens, J., Doignon, Y., Eggerickx, T., Plavsic, A., Sanderson, J.-P.
10.1101/2023.09.04.23295014 — Posted: 2023-09-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).